Literature DB >> 17137434

Testosterone: use, misuse and abuse.

David J Handelsman1.   

Abstract

Testosterone is among the oldest drugs in medicine. It has a long efficacy and safety record for its prime role of androgen replacement therapy in men with androgen deficiency. Testosterone and synthetic analogue androgens have also been used in pharmacological androgen therapy (PAT) to produce androgenic effects on marrow, muscle or bone. Although PAT is increasingly being superseded by newer, more expensive drugs, androgens remain cost-effective in many older applications. Androgen misuse is the systematic over-prescribing for unproven medical indications. Misuse is increasingly evident for male ageing ("andropause") and some other clinical conditions. Further trials for new indications for androgens require reliable safety data, but rising costs may make it increasingly attractive to circumvent the need for evidence by promoting off-label mass marketing. Androgen abuse is the illicit self-administration of often massive doses of androgens for non-medical purposes - notably power sports and body building. In parallel with effective detection reducing androgen abuse in elite sports, more focus is needed on non-sporting cosmetic, recreational and occupational androgen abuse. Despite ongoing androgen misuse and abuse, testosterone remains under-prescribed for younger men with classical androgen deficiency that frequently remains undiagnosed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17137434     DOI: 10.5694/j.1326-5377.2006.tb00642.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  9 in total

Review 1.  Aging biology and novel targets for drug discovery.

Authors:  David G Le Couteur; Andrew J McLachlan; Ronald J Quinn; Stephen J Simpson; Rafael de Cabo
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-06-21       Impact factor: 6.053

2.  Waist-to-height ratio as a predictor of serum testosterone in ageing men with symptoms of androgen deficiency.

Authors:  Carolyn A Allan; Roger E Peverill; Boyd Jg Strauss; Elise A Forbes; Robert I McLachlan
Journal:  Asian J Androl       Date:  2011-04-11       Impact factor: 3.285

3.  Low serum testosterone and mortality in older men.

Authors:  Gail A Laughlin; Elizabeth Barrett-Connor; Jaclyn Bergstrom
Journal:  J Clin Endocrinol Metab       Date:  2007-10-02       Impact factor: 5.958

4.  Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism.

Authors:  Jin Wook Kim; Du Geon Moon
Journal:  Korean J Urol       Date:  2011-11-17

5.  Histological changes in testes of rats treated with testosterone, nandrolone, and stanozolol.

Authors:  Siti Syairah Mohd Mutalip; Gurmeet Kaur Surindar Singh; Aishah Mohd Shah; Mashani Mohamad; Vasudevan Mani; Siti Nooraishah Hussin
Journal:  Iran J Reprod Med       Date:  2013-08

6.  Grape Seed Proanthocyanidin Ameliorates Cardiac Toxicity Induced by Boldenone Undecylenate through Inhibition of NADPH Oxidase and Reduction in the Expression of NOX2 and NOX4.

Authors:  Ehab Tousson; Rehab Mohmed Elgharabawy; Thanaa Ahmed Elmasry
Journal:  Oxid Med Cell Longev       Date:  2018-07-05       Impact factor: 6.543

7.  Testosterone replacement therapy in blood donors modulates erythrocyte metabolism and susceptibility to hemolysis in cold storage.

Authors:  Keisha Alexander; Kelsey Hazegh; Fang Fang; Derek Sinchar; Joseph E Kiss; Grier P Page; Angelo DʼAlessandro; Tamir Kanias
Journal:  Transfusion       Date:  2020-10-18       Impact factor: 3.157

8.  Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification.

Authors:  Dongxing Zhu; Patrick W F Hadoke; Junxi Wu; Alex T Vesey; Daniel A Lerman; Marc R Dweck; David E Newby; Lee B Smith; Vicky E MacRae
Journal:  Sci Rep       Date:  2016-04-20       Impact factor: 4.379

9.  Male hypogonadism in a patient with Cogan syndrome.

Authors:  Maja Radman; Ognjen Kraus; Miljenko Solter
Journal:  Ann Saudi Med       Date:  2008 Nov-Dec       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.